证券时报e公司讯，企查查APP显示，近日，华熙生物科技（天津）有限公司发生工商变更，注册资本 由2亿元增至14亿元，增幅600%。 企查查信息显示，该公司成立于2018年，法定代表人为郭珈均，经营范围含药品生产、药用辅料生产、 药品批发、药品互联网信息服务等，由华熙生物全资持股。 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥1,064,002,047.03, representing a decrease of 7.14% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was ¥20,258,275.61, down 77.44% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥10,583,321.09, a decrease of 85.37% compared to the previous year[2]. - The net cash flow from operating activities for Q3 2024 was ¥9,433,742.96, down 80.53% year-on-year[2]. - The basic earnings per share for Q3 2024 was ¥0.04, a decrease of 78.95% compared to the same period last year[3]. - Total operating revenue for the first three quarters of 2024 was approximately ¥3.87 billion, a decrease of 8.2% compared to ¥4.22 billion in the same period of 2023[14]. - Net profit for the first three quarters of 2024 was approximately ¥359 million, down 29.2% from ¥507 million in the same period of 2023[15]. - Operating profit for the first three quarters of 2024 was approximately ¥436 million, a decrease of 28.6% compared to ¥611 million in the same period of 2023[15]. - The basic earnings per share for the first three quarters of 2024 were ¥0.75, down from ¥1.07 in the same period of 2023[16]. Research and Development - The total R&D investment for Q3 2024 was ¥112,579,760.38, an increase of 24.52% year-on-year, accounting for 10.58% of operating revenue[3]. - Research and development expenses for the first three quarters of 2024 were approximately ¥313 million, an increase of 13.0% compared to ¥277 million in the same period of 2023[14]. Assets and Liabilities - The total assets at the end of the reporting period were ¥8,687,961,992.22, an increase of 2.57% compared to the end of the previous year[3]. - As of September 30, 2024, the total assets of the company amounted to RMB 8,687,961,992.22, an increase from RMB 8,470,008,293.83 at the end of 2023, reflecting a growth of approximately 2.58%[12]. - The company's total current liabilities decreased to RMB 1,136,227,866.53 from RMB 1,220,791,687.05, a reduction of approximately 6.9%[13]. - Total liabilities as of the end of the third quarter of 2024 were approximately ¥1.63 billion, an increase of 9.9% from ¥1.49 billion at the end of the third quarter of 2023[14]. - The company's total non-current assets reached RMB 6,005,480,452.74, up from RMB 5,347,153,037.58, reflecting an increase of about 12.2%[13]. Shareholder Information - The company reported a total of 32,273 common shareholders at the end of the reporting period[7]. - The largest shareholder, Huaxi Xinyu Investment Co., Ltd., held 58.86% of the shares[7]. - The company did not report any significant changes in the top 10 shareholders or their participation in margin trading activities during the reporting period[12]. Cash Flow - Cash flow from operating activities for the first three quarters of 2024 was approximately ¥4.18 billion, a decrease of 10.7% compared to ¥4.68 billion in the same period of 2023[17]. - Cash outflow from investment activities totaled approximately 953.74 million, a decrease from 1.85 billion in the previous period[19]. - Net cash flow from investment activities was negative at approximately -306.09 million, compared to -378.60 million last year[19]. - Cash inflow from financing activities was 100 million, an increase from 51.72 million in the previous period[19]. - Cash outflow from financing activities totaled approximately 449.70 million, slightly down from 465.54 million last year[19]. - Net cash flow from financing activities was negative at -349.70 million, compared to -413.83 million in the previous period[19]. - The ending balance of cash and cash equivalents was approximately 434.81 million, a decrease from 692.96 million in the previous period[19]. - The company's cash and cash equivalents decreased to RMB 511,521,498.37 from RMB 1,168,717,886.67, indicating a decline of about 56.3%[12]. Other Information - The company has adopted new accounting standards starting in 2024, which may affect financial reporting[20].

(一) 审议通过《关于审议公司 2024 年第三季度报告的议案》 表决结果：9 票赞成，0 票弃权，0 票反对。 证券代码：688363 证券简称：华熙生物 公 告 编 号 ： 2024- 036 华熙生物科技股份有限公司 第二届董事会第十五次会议决议公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 2024 年 10 月 30 日华熙生物科技股份有限公司（以下简称"公司"或"华熙生 物"）于公司会议室以现场会议结合通讯方式召开了第二届董事会第十五次会议， 会议通知已于 2024 年 10 月 25 日以电子邮件形式发出。本次会议由董事长赵燕 女士主持，应出席董事 9 人，实际出席并表决董事 9 人，公司监事及部分高级管 理人员列席了本次董事会。会议的召开及程序符合《中华人民共和国公司法》 《公司章程》等相关法律法规的规定。 二、董事会会议审议情况 本议案尚需提交股东大会审议。 (三) 审议通过《关于提议召开临时股东大会的议案》 表决结果：9 票赞成，0 票弃权，0 票反对。 本议案在呈交董事会审 ...

关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 拟聘任的会计师事务所名称：致同会计师事务所（特殊普通合伙） 一、 拟聘任会计师事务所的基本情况 证券代码：688363 证券简称：华熙生物 公告编号：2024-038 华熙生物科技股份有限公司 （二） 项目信息 1. 基本信息 项目组 成员 姓名 何时成 为注册 会计师 何时开 始从事 上市公 司审计 何时开 始在本 所执业 何时开 始为本 公司提 供审计 服务 近三年签署或复核 上市公司审计报告 情况 项目合 伙人 钱华丽 2009 年 2007 年 2015 年 2024 年 近三年签署中科软、 药康生物、方大新材 上市公司年度审计 报告 签字注 册会计 师 张国静 2020 年 2007 年 2020 年 2021 年 近三年签署中科软、 药康生物、中兴商 业、华熙生物、方大 （一） 机构信息 1. 基本信息 | 名称 | 致同会计师事务所（特殊普通合伙），前身是 | | 1981 年成立的 | | --- | --- | ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 2024 年 10 月 30 日华熙生物科技股份有限公司（以下简称"公司"）以现场 结合通讯方式召开了第二届监事会第十一次会议，会议通知及会议材料已于 2024 年 10 月 25 日以电子邮件形式发出。本次会议由监事会主席于静主持，应 出席监事 3 人，实际出席并表决的监事 3 人。会议的召开及程序符合《中华人民 共和国公司法》《公司章程》及公司《监事会议事规则》的相关规定。 二、监事会会议审议情况 (一) 审议通过《关于审议公司 2024 年第三季度报告的议案》 表决结果：同意 3 票，反对 0 票，弃权 0 票。 证券代码：688363 证券简称：华熙生物 公告编号：2024-037 华熙生物科技股份有限公司 第二届监事会第十一次会议决议公告 具体内容详见公司于 2024 年 10 月 31 日在上海证券交易所网站 （www.sse.com.cn）披露的《华熙生物科技股份有限公司 2024 年第三季度报告》。 (二) 审议通过《关于续聘公司 20 ...

证券代码：688363 证券简称：华熙生物 公告编号：2024-035 华熙生物科技股份有限公司 部分首次公开发行限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 283,500,000 股。 本次股票上市流通总数为 283,500,000 股。 本次股票上市流通日期为 2024 年 11 月 6 日。 公司实际控制人赵燕承诺： 一、 本次上市流通的限售股类型 根据中国证券监督管理委员会于 2019 年 9 月 29 日出具的《关于同意华熙生 物科技股份有限公司首次公开发行股票注册的批复》（证监许可[2019]1796 号），华 熙生物科技股份有限公司（以下简称"公司"）向社会公开发行人民币普通股 49,562,556 股，发行后公司总股本为 480,000,000 股。其中有流通限制或限售安排 的股票数量为 434,334,363 股，无流通限制及限售安排的股票数量为 45,665,637 股， 股票详情如下： | 股票类型 ...

华泰联合证券有限责任公司 关于华熙生物科技股份有限公司 除上述情况外，本次上市流通的限售股形成后至本核查意见出具之日，公司 股本数量未发生变化。截至本核查意见出具日，公司总股本为 481,678,242 股。 本次上市流通的限售股为公司控股股东华熙昕宇投资有限公司（以下简称 "华熙昕宇"）持有的首次公开发行限售股，限售期限为自公司股票上市之日起 六十个月，对应股票数量 283,500,000 股，占公司总股本的 58.86%，该部分限售 部分首次公开发行限售股上市流通的核查意见 1 华泰联合证券有限责任公司（以下简称"华泰联合"或"保荐机构"）作为 华熙生物科技股份有限公司（以下简称"华熙生物"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管 指引第 1 号——规范运作》等相关规定，对华熙生物部分首次公开发行限售股将 上市流通情况进行了审慎核查，并出具本核查意见，具体核查情况如下： 一、本次上市流通的限售股类型 股将于 2024 年 11 月 6 日起上市流通。 根据中国证券监督管理委员会于 ...

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [1] Core Views - The company has launched two new products, "Runzhi·Gege" and "Runzhi·Feiran," which enhance its competitiveness in the medical beauty sector [3] - The launch of "Runzhi·Gege," a compound solution for neck anti-aging, expands the product matrix from facial to neck treatments, focusing on anti-aging [3] - "Runzhi·Feiran" is designed for lip enhancement, further broadening the brand's appeal to different age groups seeking comprehensive beauty solutions [3] - The company is advancing 48 transformation projects in 2024, indicating a strategic focus on innovation and market adaptation [3] - The planned reduction of shares by Guoshou Chengda is seen as a normal fund expiration, which will improve the company's liquidity in the secondary market [3] Financial Projections - The company is projected to achieve revenues of 6.175 billion, 7.112 billion, and 8.305 billion yuan for 2024, 2025, and 2026 respectively, with corresponding net profits of 746 million, 886 million, and 1.040 billion yuan [4] - The expected price-to-earnings (PE) ratios for the same years are 37, 31, and 27 times [4] - Revenue growth rates are forecasted at 1.63%, 15.16%, and 16.78% for 2024, 2025, and 2026 respectively, following a decline of 4.45% in 2023 [5] Product Development and Market Strategy - The company is focusing on enhancing its product development capabilities, particularly in the field of hyaluronic acid, to support pipeline expansion [4] - The introduction of new products is expected to address the changing demands of consumers in the medical beauty market, which is becoming increasingly competitive [3][4]

Investment Rating - The report maintains a "Recommended" rating for the company, with a current price of 61.31 yuan [3]. Core Views - The company is a leader in hyaluronic acid, with a solid foundation in raw materials. The launch of new products under the Runzhi brand is expected to drive rapid growth in the medical aesthetics business. The performance of functional skincare products is undergoing adjustments, but medium to long-term growth in earnings is anticipated. The projected net profit attributable to the parent company for 2024-2026 is 712 million, 859 million, and 1.077 billion yuan, respectively, with year-on-year growth rates of +20.1%, +20.6%, and +25.4% [2][3]. Financial Forecast and Indicators - The company is expected to achieve operating revenues of 6,076 million, 6,529 million, 7,275 million, and 8,196 million yuan for the years 2024 to 2026, with growth rates of -4.5%, 7.5%, 11.4%, and 12.7% respectively [3][7]. - The net profit attributable to the parent company is forecasted to be 593 million, 712 million, 859 million, and 1,077 million yuan for the same period, with growth rates of -39.0%, 20.1%, 20.6%, and 25.4% [3][7]. - Earnings per share are projected to be 1.23, 1.48, 1.78, and 2.24 yuan for 2024 to 2026 [3][9]. - The price-to-earnings (PE) ratios for 2024, 2025, and 2026 are expected to be 50, 41, and 34, respectively, indicating a decrease in valuation over time [3][9]. Product Launches and Market Position - The company launched two new medical aesthetic products, "Runzhi·Gege" and "Runzhi·Feiran," on October 13, 2024. "Runzhi·Feiran" focuses on lip filling, enhancing the facial anti-aging product matrix, while "Runzhi·Gege" targets neck wrinkle correction, filling a gap in the neck anti-aging market [2]. - The introduction of the collagen tightening cream by the Runbaiyan brand on September 27, 2024, further strengthens the company's competitive position in the anti-aging sector and aims to meet diverse consumer needs through a combination of medical and cosmetic products [2].

证券代码：688363 证券简称：华熙生物 公告编号：2024-034 大股东持股的基本情况 截至本公告披露日，国寿成达（上海）健康产业股权投资中心（有限合伙）（以 下简称"国寿成达"）直接持有华熙生物科技股份有限公司（以下简称"本公司"） 股份数量为 34,433,286 股，占本公司总股本的 7.15%。上述股份全部为本公司首 次公开发行前股份，并已于 2022 年 11 月 7 日起上市流通。 减持计划的主要内容 国寿成达计划根据市场情况通过集中竞价、大宗交易的方式减持其所持有的本公 司股份合计不超过 12,041,955 股，拟减持股份数量占本公司总股本的比例合计不 超过 2.50%，其中以集中竞价方式减持比例不超过 1.00%，减持数量不超过 4,816,782 股；以大宗交易方式减持比例不超过 1.50%，减持数量不超过 7,225,173 股，减持期间为本公告披露 15 个交易日后 3 个月内，即 2024 年 10 月 31 日至 2025 年 1 月 28 日。 若计划减持期间本公司有送股、转增股本、配股、回购注销等股份变动事项，上 述股份数量做相应的调整，减持比例不变。 1 一、减持主体的 ...